Oliver Ackaert
Beerse, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Viral Dynamic Model-Informed Dose Selection of Mosnodenvir Prophylaxis against DENV-3 in a Controlled Human Infection Model.
Journal: Clinical pharmacology and therapeutics
Published: April 02, 2026
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus.
Journal: British journal of clinical pharmacology
Published: October 22, 2025
Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection.
Journal: Journal of the Royal Society, Interface
Published: October 03, 2025
Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis B.
Journal: Clinical pharmacology and therapeutics
Published: October 17, 2024
Evaluation of the Effect of Loperamide on the Cardiac Repolarization Interval Using Exposure-Response Analysis.
Journal: Clinical and translational science
Published: July 30, 2024
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
Journal: European journal of drug metabolism and pharmacokinetics
Published: April 28, 2024
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).
Journal: European journal of drug metabolism and pharmacokinetics
Published: April 28, 2024
The AAPS Journal Theme Issue: "Perspectives on Clinical Drug Development of Long-Acting Injectables".
Journal: The AAPS journal
Published: October 23, 2023
Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice.
Journal: CPT: pharmacometrics & systems pharmacology
Published: October 16, 2023
Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics.
Journal: PLoS computational biology
Published: July 21, 2023
Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: January 12, 2023
Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.
Journal: Nature
Published: June 29, 2022
Last Updated: 09/26/2026